New insights into the neurobiology, diagnosis, and treatment of mood disorders

Por Zarate, Carlos A.
Publicado em 2013

What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments?

Por Zarate, Carlos A.
Publicado no Am J Geriatr Psychiatry (2017)

Magnetic Resonance Spectroscopy Studies of the Glutamatergic System in Mood Disorders: A Pathway to Diagnosis, Novel Therapeutics, and Personalized Medicine?

Por Salvadore, Giacomo, Zarate, Carlos A.
Publicado em 2010

The Role of AMPA Receptor Modulation in the Treatment of Neuropsychiatric Diseases

Por Zarate, Carlos A., Manji, Husseini K.
Publicado em 2008

A Review of the Preclinical and Clinical Evidence for Protein Kinase C as a Target for Drug Development for Bipolar Disorder

Por DiazGranados, Nancy, Zarate, Carlos A.
Publicado em 2008

Putative Drugs and Targets for Bipolar Disorder

Por Zarate, Carlos A., Manji, Husseini K.
Publicado em 2008

Protein Kinase C Inhibitors: Rationale for Use and Potential in the Treatment of Bipolar Disorder

Por Zarate, Carlos A., Manji, Husseini K.
Publicado em 2009

Proof of Concept Trials in Bipolar Disorder and Major Depressive Disorder: A Translational Perspective in the Search for Improved Treatments

Por Machado-Vieira, Rodrigo, Zarate, Carlos A.
Publicado em 2011

Current Status of Ketamine and Related Compounds for Depression

Por Mathews, Daniel C., Zarate, Carlos A.
Publicado em 2013

Ketamine, Sleep, and Depression: Current Status and New Questions

Por Duncan, Wallace C., Zarate, Carlos A.
Publicado em 2013

Ketamine for depression: evidence, challenges and promise

Por Zarate, Carlos A, Niciu, Mark J
Publicado no World Psychiatry (2015)

Pulsed Intravenous Administration of Scopolamine Produces Rapid Antidepressant Effects and Modest Side Effects

Por Furey, Maura L., Zarate, Carlos A.
Publicado no J Clin Psychiatry (2013)

Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide

Por Zarate, Carlos A., Machado-Vieira, Rodrigo
Publicado no Biol Psychiatry (2015)

GSK-3: a key regulatory target for ketamine’s rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput

Por Zarate, Carlos A, Machado-Vieira, Rodrigo
Publicado no Bipolar Disord (2016)

Preventing Suicide: A Multicausal Model Requires Multimodal Research and Intervention

Por Ballard, Elizabeth D., Zarate, Carlos A.
Publicado no Bipolar Disord (2018)

Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics?

Por Nugent, Allison C., Zarate, Carlos A.
Publicado no Biol Psychiatry Cogn Neurosci Neuroimaging (2017)

Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression

Por Lener, Marc S., Kadriu, Bashkim, Zarate, Carlos A.
Publicado no Drugs (2017)

Novel Glutamatergic Treatments for Severe Mood Disorders

Por Park, Minkyung, Niciu, Mark J., Zarate, Carlos A.
Publicado no Curr Behav Neurosci Rep (2015)

Ketamine Mechanism of Action: Separating the Wheat from the Chaff

Por Gould, Todd D, Zanos, Panos, Zarate, Carlos A
Publicado no Neuropsychopharmacology (2017)

The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders

Por Machado-Vieira, Rodrigo, Manji, Husseini K., Zarate, Carlos A.
Publicado em 2009